tiprankstipranks
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
PremiumPress ReleasesRecursion Provides Business Updates and Reports First Quarter 2024 Financial Results
1M ago
Recursion Pharmaceuticals reports Q1 EPS (39c), consensus (42c)
PremiumThe Fly
Recursion Pharmaceuticals reports Q1 EPS (39c), consensus (42c)
1M ago
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
PremiumPress Releases
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
1M ago
Recursion Pharmaceuticals (NASDAQ:RXRX) AI-Driven Drug Discovery Offers Promising Upside
PremiumMarket NewsRecursion Pharmaceuticals (NASDAQ:RXRX) AI-Driven Drug Discovery Offers Promising Upside
2M ago
Recursion Pharmaceuticals appoints Khan as Chief R&D Officer, CCO
PremiumThe Fly
Recursion Pharmaceuticals appoints Khan as Chief R&D Officer, CCO
2M ago
Recursion Pharmaceuticals Welcomes New Director and C-Suite Executive
PremiumCompany Announcements
Recursion Pharmaceuticals Welcomes New Director and C-Suite Executive
2M ago
Recursion Pharmaceuticals call volume above normal and directionally bullish
PremiumThe FlyRecursion Pharmaceuticals call volume above normal and directionally bullish
3M ago
Unusually active option classes on open March 14th
PremiumThe Fly
Unusually active option classes on open March 14th
3M ago
Recursion Pharmaceuticals call volume above normal and directionally bullish
PremiumThe Fly
Recursion Pharmaceuticals call volume above normal and directionally bullish
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100